https://simplecast.com The IDI The IDI is a podcast by and for market access professionals. Each episode, we conduct in-depth interviews to get payer insights that help you optimize your value strategy and commercialization – and give people access to the heath care they deserve. The IDI is presented by Valuate Health Consultancy. Follow Valuate on LinkedIn or visit us at ValuateHealth.com to learn more. en Wed, 1 May 2024 04:00:00 +0000 Wed, 1 May 2024 04:00:14 +0000 https://theidi.simplecast.com The IDI https://image.simplecastcdn.com/images/9660dd78-6154-402f-87c9-4f85da5cd51a/0d2a0f98-2268-4f07-93dc-0f411170596e/3000x3000/masthead-square-the-idi.jpg?aid=rss_feed https://theidi.simplecast.com episodic The IDI is a podcast by and for market access professionals. Each episode, we conduct in-depth interviews to get payer insights that help you optimize your value strategy and commercialization – and give people access to the heath care they deserve. The IDI is presented by Valuate Health Consultancy. Follow Valuate on LinkedIn or visit us at ValuateHealth.com to learn more. Valuate Health Consultancy false https://feeds.simplecast.com/S6L7zZP1 healthcare, market acess, pharma, health care, drug, pharmaceutical Valuate Health Consultancy ira.apfel@valuatehealth.com 3e564bb2-53e3-4522-bc48-5ac0793a81fa Message Testing and Market Access What message is your prescription drug delivering?

Before manufacturers debut a new prescription drug they need to create a strategy to optimize coverage and commercialization. But part of that strategy consists of crafting a message that resonates with patients, providers and payers. And that’s where a lot of manufacturers get tripped up. 

Alex Mindlin of Valuate Health joins The IDI to explain how she validates manufacturers’ value messaging by combining strategic content and market research -- what she calls “creative market research.”

Follow Alex on LinkedIn.

Follow Valuate Health on LinkedIn or on the web.

]]> Wed, 1 May 2024 04:00:00 +0000 ira.apfel@valuatehealth.com (Valuate Health Consultancy) https://theidi.simplecast.com/episodes/message-testing-and-market-access-GX4R92Z_ What message is your prescription drug delivering?

Before manufacturers debut a new prescription drug they need to create a strategy to optimize coverage and commercialization. But part of that strategy consists of crafting a message that resonates with patients, providers and payers. And that’s where a lot of manufacturers get tripped up. 

Alex Mindlin of Valuate Health joins The IDI to explain how she validates manufacturers’ value messaging by combining strategic content and market research -- what she calls “creative market research.”

Follow Alex on LinkedIn.

Follow Valuate Health on LinkedIn or on the web.

]]> Message Testing and Market Access Valuate Health Consultancy 00:24:49 Alex Mindlin, a Principal, with Valuate Health joins The IDI host Ira Apfel to explain message testing and market access -- why it's important for pharma and how to improve it. Alex Mindlin, a Principal, with Valuate Health joins The IDI host Ira Apfel to explain message testing and market access -- why it's important for pharma and how to improve it. false full 26 5df5cca7-e1f1-483c-a9f4-aafd2c253f0c Social Determinants of Health and Market Access Many pharmaceutical companies say attacking health inequities is a strategic objective, but addressing the topic is hard to do. Why is this so? 

This episode's guest, Elisa Remoundos,  Senior Vice President and Group Creative Director for Entrée Health, believes that for pharma and market access to tackle health inequities they need to rethink the social determinants of health that can have a huge impact on adherence, compliance, health outcomes, and societal burdens.

Elisa also wrote about SDoH and market acccess here. 

Follow Elisa on LinkedIn. 

Follow Valuate on LinkedIn or learn more here.

]]> Mon, 1 Apr 2024 04:00:00 +0000 ira.apfel@valuatehealth.com (Valuate Health Consultancy) https://theidi.simplecast.com/episodes/social-determinants-of-health-and-market-access-3uv3z3O5 Many pharmaceutical companies say attacking health inequities is a strategic objective, but addressing the topic is hard to do. Why is this so? 

This episode's guest, Elisa Remoundos,  Senior Vice President and Group Creative Director for Entrée Health, believes that for pharma and market access to tackle health inequities they need to rethink the social determinants of health that can have a huge impact on adherence, compliance, health outcomes, and societal burdens.

Elisa also wrote about SDoH and market acccess here. 

Follow Elisa on LinkedIn. 

Follow Valuate on LinkedIn or learn more here.

]]> Social Determinants of Health and Market Access Valuate Health Consultancy 00:25:25 Elisa Remoundos, Senior Vice President and Group Creative Director for Entrée Health, discusses social determinants of health and market access. Elisa Remoundos, Senior Vice President and Group Creative Director for Entrée Health, discusses social determinants of health and market access. market access, healthcare, biotech, social determinants of health, health equity, pharma false full 25 ff640607-6bc3-4ca5-b986-0af18a8000f5 A Payer’s Perspective on Prior Authorization What do payers think about prior authorization? 

Dr. Andrew Hertler is Chief Medical Officer at Evolent Health. He recently co-authored an op-ed about prior authorization, touching on gold-carding, a controversial solution to addressing prior authorization challenges. 

Joining Hertler is regular guest John Hennessy, a Principal with Valuate. 

Topics include:

  • Why exceptions can sometimes be problematic.
  • What happens after a prior authorization is rejected.
  • Pathways: Who makes the decisions? How are they updated?
  • How should pharma  think about payers?
  • What can manufacturers and market access do to help pathways?

Follow Andrew on  LinkedIn. 

Follow Valuate on LinkedIn

Learn more about Valuate.

]]> Mon, 4 Mar 2024 05:00:00 +0000 ira.apfel@valuatehealth.com (Valuate Health Consultancy) https://theidi.simplecast.com/episodes/a-payers-perspective-on-prior-authorization-NeDlGMnt What do payers think about prior authorization? 

Dr. Andrew Hertler is Chief Medical Officer at Evolent Health. He recently co-authored an op-ed about prior authorization, touching on gold-carding, a controversial solution to addressing prior authorization challenges. 

Joining Hertler is regular guest John Hennessy, a Principal with Valuate. 

Topics include:

  • Why exceptions can sometimes be problematic.
  • What happens after a prior authorization is rejected.
  • Pathways: Who makes the decisions? How are they updated?
  • How should pharma  think about payers?
  • What can manufacturers and market access do to help pathways?

Follow Andrew on  LinkedIn. 

Follow Valuate on LinkedIn

Learn more about Valuate.

]]> A Payer’s Perspective on Prior Authorization Valuate Health Consultancy 00:36:09 Our recent episode about prior authorization was one of our most popular episodes so, to continue the conversation, we invited a payer executive, Dr. Andrew Hertler, on to the podcast get his perspective. Hertler is Chief Medical Officer at Evolent Health. Hertler recently co-authored an op-ed about prior authorization. In it, he touched on gold-carding, a controversial solution to addressing prior authorization challenges. Our recent episode about prior authorization was one of our most popular episodes so, to continue the conversation, we invited a payer executive, Dr. Andrew Hertler, on to the podcast get his perspective. Hertler is Chief Medical Officer at Evolent Health. Hertler recently co-authored an op-ed about prior authorization. In it, he touched on gold-carding, a controversial solution to addressing prior authorization challenges. market access, healthcare, biotech, prior authorization, pharma false full 24 66b54a14-2b84-4a59-bbf5-2d74f9ddd19d What Do Payers Think About Market Access? It’s no secret that pharmaceutical manufacturers and payers don’t always see eye to eye.

But in order for pharma market access to do its job it needs to better understand payers -- how  they think, what keeps them up at night, and what’s trending.

That’s why Valuate conducted its Second Annual Market Access survey late last year. The goal was to better understand payer perspectives on everything from the Inflation Reduction Act to biosimilars to gold bagging. 

Tony Gibson, a Principal with Valuate Health, returns to The IDI to break down the results. You can also contact Tony if you want an exclusive readout of the survey.

Follow Tony on  LinkedIn. 

Follow Valuate on LinkedIn

Learn more about Valuate.

]]> Wed, 31 Jan 2024 05:00:00 +0000 ira.apfel@valuatehealth.com (Valuate Health Consultancy) https://theidi.simplecast.com/episodes/what-do-payers-think-about-market-access-lY6FqOEo It’s no secret that pharmaceutical manufacturers and payers don’t always see eye to eye.

But in order for pharma market access to do its job it needs to better understand payers -- how  they think, what keeps them up at night, and what’s trending.

That’s why Valuate conducted its Second Annual Market Access survey late last year. The goal was to better understand payer perspectives on everything from the Inflation Reduction Act to biosimilars to gold bagging. 

Tony Gibson, a Principal with Valuate Health, returns to The IDI to break down the results. You can also contact Tony if you want an exclusive readout of the survey.

Follow Tony on  LinkedIn. 

Follow Valuate on LinkedIn

Learn more about Valuate.

]]> What Do Payers Think About Market Access? Valuate Health Consultancy 00:27:09 To better understand payer perceptions of pharmaceutical manufacturers, Valuate conducted its Second Annual Market Access Survey -- and the results are eye-opening. Tony Gibson returns to The IDI to break down all of the results. To better understand payer perceptions of pharmaceutical manufacturers, Valuate conducted its Second Annual Market Access Survey -- and the results are eye-opening. Tony Gibson returns to The IDI to break down all of the results. market access, insurer, pharmaceutical, payer, biotech, biosimilar, pharma false full 23 79b8b64d-f1d9-4bdf-9585-416dcbdef604 Is Hub Optimization the Key for Drug Launches? So you’ve developed a great new specialty drug but will patients and providers utilize your therapy correctly? A great hub can  help but implementing one is no easy task. 

Justine Hughes, a vice president with Archbow Consulting, joins The IDI to explain where pharma and biotech hubs stumble -- and how they can succeed. 

Follow Justine Hughes on LinkedIn. 

Follow Valuate on LinkedIn. 

Learn more about Valuate.

]]> Wed, 3 Jan 2024 05:00:00 +0000 ira.apfel@valuatehealth.com (Valuate Health Consultancy) https://theidi.simplecast.com/episodes/is-hub-optimization-the-key-for-drug-launches-foz840_f So you’ve developed a great new specialty drug but will patients and providers utilize your therapy correctly? A great hub can  help but implementing one is no easy task. 

Justine Hughes, a vice president with Archbow Consulting, joins The IDI to explain where pharma and biotech hubs stumble -- and how they can succeed. 

Follow Justine Hughes on LinkedIn. 

Follow Valuate on LinkedIn. 

Learn more about Valuate.

]]> Is Hub Optimization the Key for Drug Launches? Valuate Health Consultancy 00:26:52 Justine Hughes of Archbow Consulting explains why hub implementation is the key to a successful drug launch for pharma and market access. Hughes has led hub implementations for years so she's got some great advice -- and some amazing stories to tell. Justine Hughes of Archbow Consulting explains why hub implementation is the key to a successful drug launch for pharma and market access. Hughes has led hub implementations for years so she's got some great advice -- and some amazing stories to tell. market access, prescription drug, biotech, hub, pharma, specialty drug false full 22 32599dca-d059-4ac6-8406-56267fdf2957 Politics and Prescription Drugs: What's Ahead in 2024 The new year will be critical for pharma and market access. The industry will need to turn its attention back to the Inflation Reduction Act as the first 10 drugs are up for negotiation with the feds. Plus, there's the small matter of electing a new President. 

Al Jackson joins the IDI to help break down what it all means and where all this activity in Washington is headed. An attorney by training, Al was most recently EVP and head of health and public affairs at Ketchum.

Follow Al Jackson on LinkedIn. 

Follow Valuate on LinkedIn. 

Learn more about Valuate. 

]]> Fri, 1 Dec 2023 05:00:00 +0000 ira.apfel@valuatehealth.com (Valuate Health Consultancy) https://theidi.simplecast.com/episodes/politics-and-prescription-drugs-whats-ahead-in-2024-vb3uA_yK The new year will be critical for pharma and market access. The industry will need to turn its attention back to the Inflation Reduction Act as the first 10 drugs are up for negotiation with the feds. Plus, there's the small matter of electing a new President. 

Al Jackson joins the IDI to help break down what it all means and where all this activity in Washington is headed. An attorney by training, Al was most recently EVP and head of health and public affairs at Ketchum.

Follow Al Jackson on LinkedIn. 

Follow Valuate on LinkedIn. 

Learn more about Valuate. 

]]> Politics and Prescription Drugs: What's Ahead in 2024 Valuate Health Consultancy 00:31:16 2024 is just a month away; what will the new year hold for pharma and market access? Everything is up for grabs -- from the fate of the Inflation Reduction Act to the White House. Al Jackson of Valuate joins the IDI to explain what's a stake. 2024 is just a month away; what will the new year hold for pharma and market access? Everything is up for grabs -- from the fate of the Inflation Reduction Act to the White House. Al Jackson of Valuate joins the IDI to explain what's a stake. false full 21 4d1b853c-0b79-4c3a-8bab-111fca1b9bd2 Fighting Breast Cancer is Not a Solitary Struggle Getting a cancer diagnosis and navigating treatment can be a lonely experience, as guest Cora Meese shares on this episode of The IDI. 

Thanks to early detection, Cora is now a breast cancer survivor, but she didn’t get there on her own. 

With the help of friends and family, including podcast guest John Hennessey, Cora was able to successfully navigate her oncology journey, and connect with groups like the Young Survival Coalition. 

As we recognize Breast Cancer Awareness Month, listen to Cora share her personal journey and reflect on how her insider knowledge as a cancer patient has impacted her work in market access.  

Cora Meese, MBA, is Executive Vice President, Director of Client Services, for Entree Health. 

John Hennessy is a principal with Valuate Health and Vice President of the Board of Directors of the Young Survival Coalition.

 Follow Valuate on LinkedIn. 

]]> Thu, 12 Oct 2023 14:44:03 +0000 ira.apfel@valuatehealth.com (Valuate Health Consultancy) https://theidi.simplecast.com/episodes/fighting-breast-cancer-is-not-a-solitary-struggle-n3j3F_47 Getting a cancer diagnosis and navigating treatment can be a lonely experience, as guest Cora Meese shares on this episode of The IDI. 

Thanks to early detection, Cora is now a breast cancer survivor, but she didn’t get there on her own. 

With the help of friends and family, including podcast guest John Hennessey, Cora was able to successfully navigate her oncology journey, and connect with groups like the Young Survival Coalition. 

As we recognize Breast Cancer Awareness Month, listen to Cora share her personal journey and reflect on how her insider knowledge as a cancer patient has impacted her work in market access.  

Cora Meese, MBA, is Executive Vice President, Director of Client Services, for Entree Health. 

John Hennessy is a principal with Valuate Health and Vice President of the Board of Directors of the Young Survival Coalition.

 Follow Valuate on LinkedIn. 

]]> Fighting Breast Cancer is Not a Solitary Struggle Valuate Health Consultancy 00:28:24 October is Breast Cancer Awareness Month, so to honor all breast cancer survivors, The IDI is doing something a little different this episode. Instead of our usual discussion of strategies and tactics to improve market access and commercialization, we invited Cora Meese of Entree Health to share her story about her breast cancer diagnosis and recovery journey. October is Breast Cancer Awareness Month, so to honor all breast cancer survivors, The IDI is doing something a little different this episode. Instead of our usual discussion of strategies and tactics to improve market access and commercialization, we invited Cora Meese of Entree Health to share her story about her breast cancer diagnosis and recovery journey. market access, cancer, oncology, breast cancer, biotech, breast cancer awareness, pharma false full 20 0ce93a41-5f82-4944-8265-2dd1167117ec Why Prior Authorization Matters for Pharma It’s hard to think of an aspect of health care more vexing than prior authorizations. In fact, prior authorizations are so frustrating that Congress is looking into a legislative solution. 

This episode of The IDI we have two guests to explain the state of prior authorization and how to improve the process. 

John Hennessy is a principal with Valuate Health with a background in oncology and cancer care.

Syam Palakurthy is co-founder and CEO of SamaCare, a company that streamlines the prior authorization process for medical benefit drugs. 

Follow Valuate on LinkedIn. 

]]> Mon, 2 Oct 2023 04:00:00 +0000 ira.apfel@valuatehealth.com (Valuate Health Consultancy) https://theidi.simplecast.com/episodes/why-prior-authorization-matters-for-pharma-P9Ln5Z58 It’s hard to think of an aspect of health care more vexing than prior authorizations. In fact, prior authorizations are so frustrating that Congress is looking into a legislative solution. 

This episode of The IDI we have two guests to explain the state of prior authorization and how to improve the process. 

John Hennessy is a principal with Valuate Health with a background in oncology and cancer care.

Syam Palakurthy is co-founder and CEO of SamaCare, a company that streamlines the prior authorization process for medical benefit drugs. 

Follow Valuate on LinkedIn. 

]]> Why Prior Authorization Matters for Pharma Valuate Health Consultancy 00:30:37 Prior authorizations are a frustrating hurdle for patients who often need immediate treatment – including those in need of prescription drugs. Guests John Hennessy of Valuate and Syam Palakurthy of SamaCare join The IDI to explain the current state of prior authorization – and what’s at stake for pharma and market access. Prior authorizations are a frustrating hurdle for patients who often need immediate treatment – including those in need of prescription drugs. Guests John Hennessy of Valuate and Syam Palakurthy of SamaCare join The IDI to explain the current state of prior authorization – and what’s at stake for pharma and market access. false full 19 a39ad9af-b243-4050-b657-2f2d20abdd16 Cancer Care, Wellness and Pharma: An Unlikely Combination Pharma and biotech have developed amazing therapies and treatments to help people living with cancer. But effective cancer care should be more than just chemo and an effective drug. 

Exercise and wellness can help. A lot.

What role should pharmaceutical manufacturers and market access teams play in exercise and wellness for cancer patients though? Do they incorporate exercise? Isn’t their cancer-fighting drug enough? 

Today’s guests believe pharma and market access should factor in exercise and wellness when treating cancer. And they’ll explain how pharma and market access can take all this into consideration.

John Hennessy is a principal with Valuate Health. He’s been on The IDI many times and he’s held many roles in the world of oncology and cancer care.

First-time IDI guest Sami Mansfield is the founder of Cancer Wellness for Life, an organization focused on developing oncology exercise resources for individuals, hospitals, and corporations. She’s been in this space for more than 20 years and was one of the first oncology exercise specialists in the United States.

Here are just a few research findings about the benefits of wellness and exercise on cancer care patients, including two articles co-authored by Sami Mansfield. 

Follow Valuate on LinkedIn or visit us at ValuateHealth.com. 

]]> Fri, 1 Sep 2023 04:00:00 +0000 ira.apfel@valuatehealth.com (Valuate Health Consultancy) https://theidi.simplecast.com/episodes/cancer-care-wellness-and-pharma-an-unlikely-combination-xavTk9tC Pharma and biotech have developed amazing therapies and treatments to help people living with cancer. But effective cancer care should be more than just chemo and an effective drug. 

Exercise and wellness can help. A lot.

What role should pharmaceutical manufacturers and market access teams play in exercise and wellness for cancer patients though? Do they incorporate exercise? Isn’t their cancer-fighting drug enough? 

Today’s guests believe pharma and market access should factor in exercise and wellness when treating cancer. And they’ll explain how pharma and market access can take all this into consideration.

John Hennessy is a principal with Valuate Health. He’s been on The IDI many times and he’s held many roles in the world of oncology and cancer care.

First-time IDI guest Sami Mansfield is the founder of Cancer Wellness for Life, an organization focused on developing oncology exercise resources for individuals, hospitals, and corporations. She’s been in this space for more than 20 years and was one of the first oncology exercise specialists in the United States.

Here are just a few research findings about the benefits of wellness and exercise on cancer care patients, including two articles co-authored by Sami Mansfield. 

Follow Valuate on LinkedIn or visit us at ValuateHealth.com. 

]]> Cancer Care, Wellness and Pharma: An Unlikely Combination Valuate Health Consultancy 00:34:21 What role should pharmaceutical manufacturers and market access teams play in exercise and wellness for cancer? Isn’t their cancer-fighting drug enough? Guests John Hennessy of Valuate Health and Sami Mansfield of Cancer Wellness for Life explain why and how pharma and market access should incorporate wellness into cancer care. What role should pharmaceutical manufacturers and market access teams play in exercise and wellness for cancer? Isn’t their cancer-fighting drug enough? Guests John Hennessy of Valuate Health and Sami Mansfield of Cancer Wellness for Life explain why and how pharma and market access should incorporate wellness into cancer care. market access, pharmaceutical, cancer, oncology, wellness, biotech, pharma, exercise false full 18 623ccf40-cc33-440b-b909-85ef61f36496 Pharma Has a Pull-Through Problem -- Is Data the Answer? Your new drug has made it to the insurers’ formulary, but will providers actually prescribe it? Pull-through challenges abound; getting physicians to prescribe your drug means training and coordinating field staff. Encouraging pharmacies to stock and recommend your drug. Educating patients. And more. Lastly, there’s the challenge of measuring success – what does successful pull-through look like anyway?

Jack Timko, Senior Principal, Valuate Health, returns to The IDI to offer his insights. 

Follow Jack on LinkedIn.

Follow Valuate on LinkedIn or visit us at ValuateHealth.com. 

]]> Tue, 1 Aug 2023 04:00:00 +0000 ira.apfel@valuatehealth.com (Valuate Health Consultancy) https://theidi.simplecast.com/episodes/pharma-has-a-pull-through-problem-is-data-the-answer-gb1UQUl1 Your new drug has made it to the insurers’ formulary, but will providers actually prescribe it? Pull-through challenges abound; getting physicians to prescribe your drug means training and coordinating field staff. Encouraging pharmacies to stock and recommend your drug. Educating patients. And more. Lastly, there’s the challenge of measuring success – what does successful pull-through look like anyway?

Jack Timko, Senior Principal, Valuate Health, returns to The IDI to offer his insights. 

Follow Jack on LinkedIn.

Follow Valuate on LinkedIn or visit us at ValuateHealth.com. 

]]> Pharma Has a Pull-Through Problem -- Is Data the Answer? Valuate Health Consultancy 00:22:18 Pull-through – the strategy and tactics designed to encourage physicians to prescribe a drug – is one of the biggest challenges pharmaceutical manufacturers and biotech firms face. Jack Timko, Senior Principal, Valuate Health, returns to The IDI to diagnose the pull-through challenges and explain how data analytics can improve pull-through success rates. Pull-through – the strategy and tactics designed to encourage physicians to prescribe a drug – is one of the biggest challenges pharmaceutical manufacturers and biotech firms face. Jack Timko, Senior Principal, Valuate Health, returns to The IDI to diagnose the pull-through challenges and explain how data analytics can improve pull-through success rates. market access, pull-through, biotech, pharma, formulary false full 17 ee2a92db-44da-43e6-a6b6-7e264d063f6f How Pharma Can Turn Data into Insights Every pharma company wants to analyze and leverage their data for other purposes. 

But what if you’re not a data scientist? Or maybe your data is messy; did you even know data can be messy?

Derek Tancredi and Terrill Paterson deal with these challenges all the time as they work with pharma and market access teams.

Derek is a consultant at Valuate Health with an MBA in Health Care Administration. Terrill Paterson is a Senior Analyst with Valuate. He holds a Masters in Statistics and a PhD in Environmental Science. 

Follow Derek on LinkedIn.

Follow Terrill on LinkedIn.

Follow Valuate on LinkedIn or visit us at ValuateHealth.com. 

]]> Sat, 1 Jul 2023 04:00:00 +0000 ira.apfel@valuatehealth.com (Valuate Health Consultancy) https://theidi.simplecast.com/episodes/how-pharma-can-turn-data-into-insights-5pWts9h0 Every pharma company wants to analyze and leverage their data for other purposes. 

But what if you’re not a data scientist? Or maybe your data is messy; did you even know data can be messy?

Derek Tancredi and Terrill Paterson deal with these challenges all the time as they work with pharma and market access teams.

Derek is a consultant at Valuate Health with an MBA in Health Care Administration. Terrill Paterson is a Senior Analyst with Valuate. He holds a Masters in Statistics and a PhD in Environmental Science. 

Follow Derek on LinkedIn.

Follow Terrill on LinkedIn.

Follow Valuate on LinkedIn or visit us at ValuateHealth.com. 

]]> How Pharma Can Turn Data into Insights Valuate Health Consultancy 00:32:12 Derek Tancredi and Terrill Paterson of Valuate Health explain how pharma market access teams can turn data into insights -- and they reveal the one thing you should never do when conducting data analysis. Derek Tancredi and Terrill Paterson of Valuate Health explain how pharma market access teams can turn data into insights -- and they reveal the one thing you should never do when conducting data analysis. market access, pharmaceutical, data analytics, data analysis, drug manufacturing, data, pharma false full 16 0d6a4586-6adc-4f45-8a85-6c0dab7cb60c ChatGPT Comes to Market Access ChatGPT, the artificial intelligence tool that generates text and allows you to have human-like conversations, was released in November of last year. 

Today, you can ask  ChatGPT to write a business plan to commercialize market access for your new prescription drug -- and it will do so in seconds.

Bill Pittenger, SVP, Director of Digital Growth & Operations for Entrée Health, is experimenting with ChatGPT and other AI tools for market access. Bill explains how and why ChatGPT and other AI tools will transform market access for the better in today's episode.

Follow Bill Pittenger on LinkedIn.

Follow Valuate on LinkedIn or visit us at ValuateHealth.com. 

]]> Mon, 5 Jun 2023 04:00:00 +0000 ira.apfel@valuatehealth.com (Valuate Health Consultancy) https://theidi.simplecast.com/episodes/chatgpt-comes-to-market-access-vhDW5YAa ChatGPT, the artificial intelligence tool that generates text and allows you to have human-like conversations, was released in November of last year. 

Today, you can ask  ChatGPT to write a business plan to commercialize market access for your new prescription drug -- and it will do so in seconds.

Bill Pittenger, SVP, Director of Digital Growth & Operations for Entrée Health, is experimenting with ChatGPT and other AI tools for market access. Bill explains how and why ChatGPT and other AI tools will transform market access for the better in today's episode.

Follow Bill Pittenger on LinkedIn.

Follow Valuate on LinkedIn or visit us at ValuateHealth.com. 

]]> ChatGPT Comes to Market Access Valuate Health Consultancy 00:27:05 ChatGPT has taken the world by storm; every industry is experimenting with the AI technology, and pharma is no exception. This episode's guest, Bill Pittenger, may be the biggest evangelist for AI in pharmaceutical market access. Bill is SVP, Director of Digital Growth & Operations for Entrée Health. ChatGPT has taken the world by storm; every industry is experimenting with the AI technology, and pharma is no exception. This episode's guest, Bill Pittenger, may be the biggest evangelist for AI in pharmaceutical market access. Bill is SVP, Director of Digital Growth & Operations for Entrée Health. market access, chatgpt, ai, midjourney, pharma, artificial intelligence false full 15 7d9df476-4442-49cc-b1b3-b48002cf411a What's Working in Hub Services Hub services sound great in theory. But in practice, hub services can be a challenge for the patient and the manufacturer. 

DeWayne Manning is a partner with Archbow Consulting and an expert on hub services. DeWayne has more than 25 years of experience advising clients on specialty products, reimbursement, patient access programs, business process optimization, technology integration, and data management  

Follow DeWayne Manning on LinkedIn.

Follow Valuate on LinkedIn or visit us at ValuateHealth.com. 

]]> Mon, 1 May 2023 04:00:00 +0000 ira.apfel@valuatehealth.com (Valuate Health Consultancy) https://theidi.simplecast.com/episodes/whats-working-in-hub-services-197eBkoS Hub services sound great in theory. But in practice, hub services can be a challenge for the patient and the manufacturer. 

DeWayne Manning is a partner with Archbow Consulting and an expert on hub services. DeWayne has more than 25 years of experience advising clients on specialty products, reimbursement, patient access programs, business process optimization, technology integration, and data management  

Follow DeWayne Manning on LinkedIn.

Follow Valuate on LinkedIn or visit us at ValuateHealth.com. 

]]> What's Working in Hub Services Valuate Health Consultancy 00:25:02 DeWayne Manning of Archbow Consulting joins The IDI to discuss hub services, those ubiquitous offerings from pharmaceutical manufacturers designed to create a single point of contact with patients. Where are hub services headed, and how can manufacturers and market access help? DeWayne Manning of Archbow Consulting joins The IDI to discuss hub services, those ubiquitous offerings from pharmaceutical manufacturers designed to create a single point of contact with patients. Where are hub services headed, and how can manufacturers and market access help? market access, patient, engagement, biotech, pharma, hub service false full 14 7c8f29d2-c6c8-4fc3-8e92-e80712e015f4 Cancer Care: Major Progress and New Challenges The good news: The cancer death rate in America has fallen 33% since 1991. 

The bad news: The cost for treatment remains a huge barrier for some patients.

One recent study put the economic and human costs of cancer in adolescents and young adults at $23.5 billion overall -- nearly $260,000 per  patient.

To get a sense of how to improve access and affordability, The IDI host Ira Apfel spoke to John Hennessy and Matt Farber.

Hennessy is a Principal at Valuate and a former executive director of the Kansas City Cancer Center, and former executive director the community cancer program at the University of Kansas Hospital. 

Farber is the vice president for Enterprise Partnerships with OffScrip Health, one of the fastest-growing patient access, impact, and content influencers in the country.  

Follow John Hennessy on LinkedIn.

Follow Matt Farber on LinkedIn.

Follow Valuate on LinkedIn or visit us at ValuateHealth.com. 

]]> Mon, 3 Apr 2023 04:00:00 +0000 ira.apfel@valuatehealth.com (Valuate Health Consultancy) https://theidi.simplecast.com/episodes/cancer-care-major-progress-and-new-challenges-An9iWizM The good news: The cancer death rate in America has fallen 33% since 1991. 

The bad news: The cost for treatment remains a huge barrier for some patients.

One recent study put the economic and human costs of cancer in adolescents and young adults at $23.5 billion overall -- nearly $260,000 per  patient.

To get a sense of how to improve access and affordability, The IDI host Ira Apfel spoke to John Hennessy and Matt Farber.

Hennessy is a Principal at Valuate and a former executive director of the Kansas City Cancer Center, and former executive director the community cancer program at the University of Kansas Hospital. 

Farber is the vice president for Enterprise Partnerships with OffScrip Health, one of the fastest-growing patient access, impact, and content influencers in the country.  

Follow John Hennessy on LinkedIn.

Follow Matt Farber on LinkedIn.

Follow Valuate on LinkedIn or visit us at ValuateHealth.com. 

]]> Cancer Care: Major Progress and New Challenges Valuate Health Consultancy 00:32:25 Treatments and therapies for cancer care have improved, but access and affordability are increasingly difficult. Guests John Hennessy of Valuate and Matt Farber of OffScrip Health explain what needs to happen next. Treatments and therapies for cancer care have improved, but access and affordability are increasingly difficult. Guests John Hennessy of Valuate and Matt Farber of OffScrip Health explain what needs to happen next. affordability, market access, access, cancer, oncology, screenings, treatment, pharma false full 13 bdfebc24-140c-4c80-a3d0-acd453aac732 What's Trending in Market Access and Pharma? A recent article in Pharmaceutical Executive listed 10 market access trends shaping the post-pandemic world -- and one of the contributors was Andrew Gottfried, CEO of Entree Health, an access and reimbursement communications agency. 

In a wide-ranging episode of The IDI, Andrew discussed global access and storytelling, the Inflation Reduction Act, the post-pandemic world, and more.

Connect with Andrew Gottfried on LinkedIn.

Follow Valuate on LinkedIn or visit us at ValuateHealth.com. 

]]> Wed, 1 Mar 2023 05:00:00 +0000 ira.apfel@valuatehealth.com (Valuate Health Consultancy) https://theidi.simplecast.com/episodes/whats-trending-in-market-access-and-pharma-nTj_sHpz A recent article in Pharmaceutical Executive listed 10 market access trends shaping the post-pandemic world -- and one of the contributors was Andrew Gottfried, CEO of Entree Health, an access and reimbursement communications agency. 

In a wide-ranging episode of The IDI, Andrew discussed global access and storytelling, the Inflation Reduction Act, the post-pandemic world, and more.

Connect with Andrew Gottfried on LinkedIn.

Follow Valuate on LinkedIn or visit us at ValuateHealth.com. 

]]> What's Trending in Market Access and Pharma? Valuate Health Consultancy 00:15:03 Andrew Gottfried, CEO of Entree Health, joins The IDI to discuss the market access trends shaping the industry right now. He discussed global access and storytelling, the Inflation Reduction Act, the post-pandemic world, and more. Andrew Gottfried, CEO of Entree Health, joins The IDI to discuss the market access trends shaping the industry right now. He discussed global access and storytelling, the Inflation Reduction Act, the post-pandemic world, and more. false full 12 5833e691-cc9b-4752-be30-136d0d8b5b2c Why the PIE Act Could Be a Big Deal for Drug Manufacturers Susan Weber is a Principal with Valuate Health. She recently authored a paper on the impact of the PIE Act, which you can read here.  

Connect with Susan Weber on LinkedIn.

Follow Valuate on LinkedIn or visit us at ValuateHealth.com.

]]> Wed, 1 Feb 2023 05:00:00 +0000 ira.apfel@valuatehealth.com (Valuate Health Consultancy) https://theidi.simplecast.com/episodes/why-the-pie-act-could-be-a-big-deal-for-drug-manufacturers-G3yRyQhs Susan Weber is a Principal with Valuate Health. She recently authored a paper on the impact of the PIE Act, which you can read here.  

Connect with Susan Weber on LinkedIn.

Follow Valuate on LinkedIn or visit us at ValuateHealth.com.

]]> Why the PIE Act Could Be a Big Deal for Drug Manufacturers Valuate Health Consultancy 00:24:18 The Pre-Approval Information Exchange Act of 2022, better known as the PIE Act, doesn’t seem very consequential at first glance. But returning guest Susan Weber thinks the PIE Act has the potential to be a real asset to pharma, market access and, ultimately, to patients. The Pre-Approval Information Exchange Act of 2022, better known as the PIE Act, doesn’t seem very consequential at first glance. But returning guest Susan Weber thinks the PIE Act has the potential to be a real asset to pharma, market access and, ultimately, to patients. market access, congress, pie act, drug manufacturer, health care, pharma, pre-approval, commercialization false full 11 49a7aa35-2e5d-43ce-a88c-3b46daa21cda The State of Market Access 2022 was a year of uncertainty for pharma and market access. So we figured it was a good time to ask  payer executives for their thoughts on the subject -- and gain some insights from their responses. 

Susan Weber, today's guest on The IDI, wrote and supervised the survey. She's the best person to interpret the findings and draw some lessons for market access professionals. 

Connect with Susan Weber on LinkedIn.

Follow Valuate on LinkedIn or visit us at ValuateHealth.com.

 

]]> Wed, 4 Jan 2023 14:57:12 +0000 ira.apfel@valuatehealth.com (Valuate Health Consultancy) https://theidi.simplecast.com/episodes/the-state-of-market-access-dpkE1Ky2 2022 was a year of uncertainty for pharma and market access. So we figured it was a good time to ask  payer executives for their thoughts on the subject -- and gain some insights from their responses. 

Susan Weber, today's guest on The IDI, wrote and supervised the survey. She's the best person to interpret the findings and draw some lessons for market access professionals. 

Connect with Susan Weber on LinkedIn.

Follow Valuate on LinkedIn or visit us at ValuateHealth.com.

 

]]> The State of Market Access Valuate Health Consultancy 00:22:38 In today's episode, we discuss the state of market access. How did pharma navigate an uncertain environment in 2022, and what lies ahead in 2023? Susan Weber, a Principal with Valuate, joins The IDI as our guest -- and she has the results of a new survey of payer executives that will help answer these questions. In today's episode, we discuss the state of market access. How did pharma navigate an uncertain environment in 2022, and what lies ahead in 2023? Susan Weber, a Principal with Valuate, joins The IDI as our guest -- and she has the results of a new survey of payer executives that will help answer these questions. market access, inflation, manufacturers, medicare, healthcare, pharma, payers, survey false full 10 d86558d8-0eec-46aa-8357-b58a965f7416 How the Inflation Reduction Act Will Impact Pharma When President Biden signed the Inflation Reduction Act into law earlier this year, he set the stage for some of the biggest changes the pharmaceutical industry has seen in years. So how should pharma prepare for the IRA? 

Diane Petrone and Jim Kenney, principal consultants with Valuate Health, join The IDI to discuss what they're hearing from pharma clients about the IRA; which aspects of the IRA  will have the biggest impact on pharma; why removing some drug rebate calculations (as laid out in the IRA) is a big deal; and more. 

Follow Valuate on LinkedIn or visit us at ValuateHealth.com.

]]> Mon, 5 Dec 2022 14:35:13 +0000 ira.apfel@valuatehealth.com (Valuate Health Consultancy) https://theidi.simplecast.com/episodes/how-the-inflation-reduction-act-will-impact-pharma-SM_En2Tv When President Biden signed the Inflation Reduction Act into law earlier this year, he set the stage for some of the biggest changes the pharmaceutical industry has seen in years. So how should pharma prepare for the IRA? 

Diane Petrone and Jim Kenney, principal consultants with Valuate Health, join The IDI to discuss what they're hearing from pharma clients about the IRA; which aspects of the IRA  will have the biggest impact on pharma; why removing some drug rebate calculations (as laid out in the IRA) is a big deal; and more. 

Follow Valuate on LinkedIn or visit us at ValuateHealth.com.

]]> How the Inflation Reduction Act Will Impact Pharma Valuate Health Consultancy 00:23:38 How should pharma respond to the Inflation Reduction Act? The IDI spoke to two market access experts, Jim Kenney and and Diane Petrone, for some advice. How should pharma respond to the Inflation Reduction Act? The IDI spoke to two market access experts, Jim Kenney and and Diane Petrone, for some advice. market access, gross to net, inflation reduction act, managed care, medicare, drug pricing, pharma false full 9 92433370-aea1-492a-ae4e-032da44ad735 Pharma and Data Analytics: What's the Right Approach? Pharmaceutical manufacturers today rely on data in everything from accelerating drug development and improving the efficacy of clinical trials to reducing safety concerns and identifying patient populations.

But the sheer amount of data can be overwhelming. Too often it’s hard to figure out where to get started in the data analytics part. What do you want to know from the data? What are the right questions to ask of the data? And is this even the right data to use?

Jack Timko, a principal with Valuate Health who leads their data analytics team, joins The IDI to help make sense of data and data analytics in pharma and market access.

Connect with Jack Timko on LinkedIn

Learn more about Valuate Health

]]> Tue, 1 Nov 2022 04:00:00 +0000 ira.apfel@valuatehealth.com (Valuate Health Consultancy) https://theidi.simplecast.com/episodes/pharma-and-data-analytics-whats-the-right-approach-aP19kYRC Pharmaceutical manufacturers today rely on data in everything from accelerating drug development and improving the efficacy of clinical trials to reducing safety concerns and identifying patient populations.

But the sheer amount of data can be overwhelming. Too often it’s hard to figure out where to get started in the data analytics part. What do you want to know from the data? What are the right questions to ask of the data? And is this even the right data to use?

Jack Timko, a principal with Valuate Health who leads their data analytics team, joins The IDI to help make sense of data and data analytics in pharma and market access.

Connect with Jack Timko on LinkedIn

Learn more about Valuate Health

]]> Pharma and Data Analytics: What's the Right Approach? Valuate Health Consultancy 00:29:45 What does data analytics mean for pharma and market access? And what do manufacturers and payers want when they ask for data and data analytics? Jack Timko, Principal, Data Analytics with Valuate Health, has some thoughts. What does data analytics mean for pharma and market access? And what do manufacturers and payers want when they ask for data and data analytics? Jack Timko, Principal, Data Analytics with Valuate Health, has some thoughts. market access, data analytics, health care, data, pharma, methodology false full 8 fa832d0a-43f0-47ae-a653-939c77bae7c7 Health Equity and Pharma: Where to Begin? Health equity is a big topic in the pharmaceutical industry right now, but the topic is so large that manufacturers don't know where to start. Tony Gibson, MHA, a Principal at Valuate Health, has some advice on how pharma can address health equity in a meaningful way.

Manufacturers have shown a “tremendous willingness to incorporate the voice of the patient,” Gibson says. But their health equity messaging tends to be the weak link. “It can come off as window dressing which minimizes this very important topic and reduces it to a catch phrase,” he says.

Connect with Tony on LinkedIn

Gibson recently contributed to a white paper on health equity and pharma.

Download the health equity and pharma white paper

]]> Tue, 4 Oct 2022 04:00:00 +0000 ira.apfel@valuatehealth.com (Valuate Health Consultancy) https://theidi.simplecast.com/episodes/health-equity-and-pharma-where-to-begin-NpR8QHVz Health equity is a big topic in the pharmaceutical industry right now, but the topic is so large that manufacturers don't know where to start. Tony Gibson, MHA, a Principal at Valuate Health, has some advice on how pharma can address health equity in a meaningful way.

Manufacturers have shown a “tremendous willingness to incorporate the voice of the patient,” Gibson says. But their health equity messaging tends to be the weak link. “It can come off as window dressing which minimizes this very important topic and reduces it to a catch phrase,” he says.

Connect with Tony on LinkedIn

Gibson recently contributed to a white paper on health equity and pharma.

Download the health equity and pharma white paper

]]> Health Equity and Pharma: Where to Begin? Valuate Health Consultancy 00:24:58 The pharmaceutical industry wants to do the right thing and address health equity. But figuring out what to do first is proving to be a challenge. Tony Gibson, a Principal at Valuate Health, shares his thoughts on how pharma can meaningfully address health equity. The pharmaceutical industry wants to do the right thing and address health equity. But figuring out what to do first is proving to be a challenge. Tony Gibson, a Principal at Valuate Health, shares his thoughts on how pharma can meaningfully address health equity. valuate, patient, sdoh, pharmaceutical, therapeutic, healthcare, health care, messaging, social determinants of health, health equity, data, pharma, health false full 7 dee14a04-f43b-479b-a346-0d67700ef05f Cancer Care: Can Two New Initiatives Help? Two new cancer care initiatives -- Medicare's  Enhancing Oncology Model and the Patient-Centered Cancer Care Certification from the American Society of Clinical Oncology, or ASCO -- aim to improve patient outcomes and fight rising costs.

Both initiatives have lofty goals, but can they attain them? And how will they impact manufacturers and market access?

Today's guest is John Hennessy, Senior Vice President, Strategist with Valuate Health Consultancy. 

The IDI is presented by Valuate Health Consultancy. 

Follow Valuate on LinkedIn to learn more.

]]> Tue, 6 Sep 2022 19:29:42 +0000 ira.apfel@valuatehealth.com (Valuate Health Consultancy) https://theidi.simplecast.com/episodes/cancer-care-can-two-new-initiatives-help-fyuxofrj Two new cancer care initiatives -- Medicare's  Enhancing Oncology Model and the Patient-Centered Cancer Care Certification from the American Society of Clinical Oncology, or ASCO -- aim to improve patient outcomes and fight rising costs.

Both initiatives have lofty goals, but can they attain them? And how will they impact manufacturers and market access?

Today's guest is John Hennessy, Senior Vice President, Strategist with Valuate Health Consultancy. 

The IDI is presented by Valuate Health Consultancy. 

Follow Valuate on LinkedIn to learn more.

]]> Cancer Care: Can Two New Initiatives Help? Valuate Health Consultancy 00:25:53 Improving cancer care is a never-ending battle. Can two new initiatives help? Valuate's John Hennessy returns to The IDI to discuss the Enhancing Oncology Model and the Patient-Centered Cancer Care Certification. Improving cancer care is a never-ending battle. Can two new initiatives help? Valuate's John Hennessy returns to The IDI to discuss the Enhancing Oncology Model and the Patient-Centered Cancer Care Certification. valuate, market access, pharmaceutical, cancer, oncology, medicare, value strategy, health equity, asco, pharma false full 6 5b4b3cbd-7094-416f-9a27-3892d623cdf9 Prescription Digital Therapeutics: Healthcare on Your Smartphone Prescription digital therapeutics is a promising new technology for patients with chronic conditions. But it comes with challenges too. Christine Castiglione, MPH, a Senior Strategy Analyst with Valuate Health Consultancy, offers her insights on prescription digital therapeutics.

Connect with guest Christine Castiglione. 

Learn more about Valuate Health.

]]> Wed, 10 Aug 2022 04:00:00 +0000 ira.apfel@valuatehealth.com (Valuate Health Consultancy) https://theidi.simplecast.com/episodes/prescription-digital-therapeutics-healthcare-on-your-smartphone-lSWTeaPP Prescription digital therapeutics is a promising new technology for patients with chronic conditions. But it comes with challenges too. Christine Castiglione, MPH, a Senior Strategy Analyst with Valuate Health Consultancy, offers her insights on prescription digital therapeutics.

Connect with guest Christine Castiglione. 

Learn more about Valuate Health.

]]> Prescription Digital Therapeutics: Healthcare on Your Smartphone Valuate Health Consultancy 00:20:40 Can you really treat your chronic condition with prescription-based software? Increasingly, you can, thanks to prescription digital therapeutics. But the new technology comes with challenges. Christine Castiglione, MPH, a Senior Strategy Analyst with Valuate Health Consultancy, offers her insights on prescription digital therapeutics. Can you really treat your chronic condition with prescription-based software? Increasingly, you can, thanks to prescription digital therapeutics. But the new technology comes with challenges. Christine Castiglione, MPH, a Senior Strategy Analyst with Valuate Health Consultancy, offers her insights on prescription digital therapeutics. market access, mental health, chronic conditions, healthcare, prescription digital therapeutics false full 5 8c5041bf-0eeb-4b36-8879-b14f0062bfaa Making Cancer Care More Affordable John Hennessy, SVP of Strategy with Valuate Health Consultancy, is well known and highly respected for his experience in cancer care. In this episode, Hennessy discusses the high cost of cancer care -- and how manufacturers, payers and clinicians are trying to address it. He also reports back from the American Society of Clinical Oncology's first in-person meeting in two years.   

BONUS: John weighs in on the big Supreme Court decision on 340B payments.  

The IDI is presented by Valuate Health Consultancy. Follow Valuate on LinkedIn or visit us at ValuateHealth.com to learn more.

 

]]> Wed, 15 Jun 2022 04:00:00 +0000 ira.apfel@valuatehealth.com (Valuate Health Consultancy) https://theidi.simplecast.com/episodes/making-cancer-care-more-affordable-lPKq_jdU John Hennessy, SVP of Strategy with Valuate Health Consultancy, is well known and highly respected for his experience in cancer care. In this episode, Hennessy discusses the high cost of cancer care -- and how manufacturers, payers and clinicians are trying to address it. He also reports back from the American Society of Clinical Oncology's first in-person meeting in two years.   

BONUS: John weighs in on the big Supreme Court decision on 340B payments.  

The IDI is presented by Valuate Health Consultancy. Follow Valuate on LinkedIn or visit us at ValuateHealth.com to learn more.

 

]]> Making Cancer Care More Affordable Valuate Health Consultancy 00:21:11 John Hennessy, SVP of Strategy with Valuate Health, discusses the high cost of cancer care -- and how manufacturers, payers and clinicians are trying to address it. BONUS: John weighs in on the big Supreme Court decision on 340B payments. John Hennessy, SVP of Strategy with Valuate Health, discusses the high cost of cancer care -- and how manufacturers, payers and clinicians are trying to address it. BONUS: John weighs in on the big Supreme Court decision on 340B payments. market access, hematology, payer, cancer care, oncology, pharmacy, social determinants of health, health equity, pharma false full 4 d00c4e69-a44d-4626-a8a9-8ba7ceaf5ac8 Specialty Pharmacy: Data, Coverage and More What's happening in specialty pharmacy and coverage? Derek Tancredi, MBA, has some thoughts. He just returned from Asembia 2022 and heard from payers, pharmacists, Dr. Scott Gottlieb, and more. 

The IDI  is presented by Valuate Health Consultancy. Follow Valuate on LinkedIn or visit us at ValuateHealth.com to learn more.

]]> Fri, 13 May 2022 04:00:00 +0000 ira.apfel@valuatehealth.com (Valuate Health Consultancy) https://theidi.simplecast.com/episodes/specialty-pharmacy-data-coverage-and-more-kjRL_3pb What's happening in specialty pharmacy and coverage? Derek Tancredi, MBA, has some thoughts. He just returned from Asembia 2022 and heard from payers, pharmacists, Dr. Scott Gottlieb, and more. 

The IDI  is presented by Valuate Health Consultancy. Follow Valuate on LinkedIn or visit us at ValuateHealth.com to learn more.

]]> Specialty Pharmacy: Data, Coverage and More Valuate Health Consultancy 00:16:15 Derek Tancredi, MBA, provides an update on the latest news in specialty pharmacy -- data, coverage and more. Derek Tancredi, MBA, provides an update on the latest news in specialty pharmacy -- data, coverage and more. market access, payer, healthcare, specialty pharmacy, pharma, reimbursement, coverage false full 3 2c9a540f-61ee-4e65-9780-c1b1a7ef4b87 AMCP Wrap-Up -- Part Two Kimberly Tsai, PharmD, and Christine Castiglione, MPH, report back from AMCP 2022 in Part Two of a  special podcast. 

In Part Two, Kimberly and Christine discuss the PIE Act, social determinants of health, and more. 

The IDI  is presented by Valuate Health Consultancy. Follow Valuate on LinkedIn or visit us at ValuateHealth.com to learn more.

]]> Fri, 15 Apr 2022 04:00:00 +0000 ira.apfel@valuatehealth.com (Valuate Health Consultancy) https://theidi.simplecast.com/episodes/amcp-wrap-up-part-two-y0ANMf4t Kimberly Tsai, PharmD, and Christine Castiglione, MPH, report back from AMCP 2022 in Part Two of a  special podcast. 

In Part Two, Kimberly and Christine discuss the PIE Act, social determinants of health, and more. 

The IDI  is presented by Valuate Health Consultancy. Follow Valuate on LinkedIn or visit us at ValuateHealth.com to learn more.

]]> AMCP Wrap-Up -- Part Two Valuate Health Consultancy 00:12:42 Kimberly Tsai, PharmD, and Christine Castiglione, MPH, report back from AMCP 2022 in Part Two of a special podcast. Kimberly Tsai, PharmD, and Christine Castiglione, MPH, report back from AMCP 2022 in Part Two of a special podcast. market access, pie act, healthcare, social determinants of health, pharma, gene therapy false full 2 5d1a3c8c-ee85-424d-944d-d3187a3661b3 AMCP Wrap-Up -- Part One Kimberly Tsai, PharmD, and Christine Castiglione, MPH, report back from AMCP 2022 in the first of a two-part special podcast. 

AMCP, presented by the Academy of Managed Care Pharmacy, is a major event in the world of pharma and market access – and there’s always lots of news and takeaways for market access professionals.

In Part One of a two-episode wrap-up, Kimberly and Christine reveal their biggest takeaways from AMCP and delve into biosimilars and why their time may finally be here. 

The IDI  is presented by Valuate Health Consultancy. Follow Valuate on LinkedIn or visit us at ValuateHealth.com to learn more.

]]> Fri, 8 Apr 2022 20:00:00 +0000 ira.apfel@valuatehealth.com (Valuate Health Consultancy) https://theidi.simplecast.com/episodes/amcp-wrapup-part-one-ESixvOBN Kimberly Tsai, PharmD, and Christine Castiglione, MPH, report back from AMCP 2022 in the first of a two-part special podcast. 

AMCP, presented by the Academy of Managed Care Pharmacy, is a major event in the world of pharma and market access – and there’s always lots of news and takeaways for market access professionals.

In Part One of a two-episode wrap-up, Kimberly and Christine reveal their biggest takeaways from AMCP and delve into biosimilars and why their time may finally be here. 

The IDI  is presented by Valuate Health Consultancy. Follow Valuate on LinkedIn or visit us at ValuateHealth.com to learn more.

]]> AMCP Wrap-Up -- Part One Valuate Health Consultancy 00:20:00 Kimberly Tsai, PharmD, and Christine Castiglione, MPH, report back from AMCP 2022 in the first of a two-part special podcast. Kimberly Tsai, PharmD, and Christine Castiglione, MPH, report back from AMCP 2022 in the first of a two-part special podcast. market access, biosimilars, healthcare, pharma, reimbursement false full 1